Related Experiment Videos
Cyclophosphamide induces osteopetrosis in rats
Research Communications in Chemical Pathology and Pharmacology
|January 1, 1981
Summary
Cyclophosphamide, a chemotherapy drug, induced osteopetrosis in rats by affecting lymphoid cells crucial for bone development. This study reveals a novel side effect impacting bone formation alongside expected immune suppression.
Area of Science:
- Immunology
- Hematology
- Pathology
- Toxicology
Background:
- Cyclophosphamide is a widely used chemotherapy agent with known immunosuppressive and hematologic effects.
- Its impact on lymphoid cells and related immune responses is well-documented.
- However, less is known about its potential effects on bone metabolism.
Purpose of the Study:
- To investigate the hematologic, immunologic, and pathologic effects of a single oral dose of cyclophosphamide in young rats.
- To identify any novel histomorphologic findings associated with cyclophosphamide administration.
Main Methods:
- Six-week-old albino rats were administered a single oral dose of cyclophosphamide.
- Hematologic, immunologic (lymphocyte counts, Concanavalin A response), and pathologic parameters were assessed.
- Histomorphologic examination of tissues, including bone, was performed.
Main Results:
- Cyclophosphamide decreased circulating lymphocytes and suppressed T cell response to Concanavalin A.
- Extramedullary hematopoiesis in the liver and spleen, and lymph node lymphocyte depletion were observed.
- A novel finding was the development of osteopetrosis, indicating altered bone morphology.
Conclusions:
- Cyclophosphamide's effects extend beyond immune suppression to include significant bone pathology.
- The drug appears to interfere with lymphoid cells involved in osteoclast formation, leading to osteopetrosis.
- This suggests a potential mechanism linking immune cell function to bone remodeling regulation.